Inovio Pharmaceuticals (INO) Reports Mixed Q3 Results
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.13 +1.80%
EPS Growth %: +60.7%
Financial Fact:
Grant and miscellaneous revenue: 9.41M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +60.7%
Financial Fact:
Grant and miscellaneous revenue: 9.41M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (AMEX: INO) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $2.64 million versus the consensus estimate of $1.87 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Ennis (EBF) Reports In-Line Q1 EPS
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
